Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

The recent approval of the first oral fecal-derived microbiota therapy to prevent the recurrence of Clostridioides difficile (C. diff) infection in patients was welcome news for physicians who've ...

Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Please provide your email address to receive an email when new articles are posted on . “C. difficile is a major problem for people in the United States; it is the most common health care-associated ...

People with pneumonia who have experienced Clostridioides difficile (C. diff) infections may be able to reduce recurrences if they take doxycycline instead of the standard treatment. The study comes ...

Please provide your email address to receive an email when new articles are posted on . Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after ...

There are about half a million C. diff infections every year in the United States. About 30,000 people die from them annually. But if you’ve had C. diff, you’re more likely to get it again. About 1 in ...

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.

Intestinal infection with the bacterium Clostridium difficile is the most frequent healthcare-linked infection in the United States. Each year it afflicts about half a million Americans, causes tens ...